ID: ALA506485

Max Phase: Preclinical

Molecular Formula: C33H31N3O6S

Molecular Weight: 597.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)Cc1c(C(=O)C(N)=O)c2c(OCC(=O)NS(=O)(=O)c3ccccc3)cc3ccccc3c2n1Cc1ccccc1

Standard InChI:  InChI=1S/C33H31N3O6S/c1-21(2)17-26-29(32(38)33(34)39)30-27(42-20-28(37)35-43(40,41)24-14-7-4-8-15-24)18-23-13-9-10-16-25(23)31(30)36(26)19-22-11-5-3-6-12-22/h3-16,18,21H,17,19-20H2,1-2H3,(H2,34,39)(H,35,37)

Standard InChI Key:  LSSDKCDZVMLLKJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 597.69

Molecular Weight (Monoisotopic): 597.1934

AlogP: 4.59

#Rotatable Bonds: 11

Polar Surface Area: 137.56

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.93

CX Basic pKa:

CX LogP: 5.29

CX LogD: 4.34

Aromatic Rings: 5

Heavy Atoms: 43

QED Weighted: 0.17

Np Likeness Score: -0.67

References

1. Oslund RC, Cermak N, Gelb MH..  (2008)  Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.,  51  (15): [PMID:18605714] [10.1021/jm800422v]

Source

Source(1):

• Scientific Literature